Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for heart inflammation sufferers: experimental drug VTX2735 enters Mid-Stage trial

NCT ID NCT06836232

Disease control Sponsor: Zomagen Biosciences Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study tests an experimental drug called VTX2735 in 50 adults with recurrent pericarditis, a condition where the heart's lining becomes inflamed and painful. The goal is to see if the drug is safe and can reduce pain and inflammation. Participants receive different doses over several weeks, and researchers monitor side effects and symptom changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants are male or female ≥ 18 years up to ≤ 75 years of age. * Capable of giving signed informed consent and able to comply with the protocol * Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event * Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks. * CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg/L must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation) * Pericarditis pain score ≥ 4 based on the 11-point NRS. * Stable doses of NSAIDs, colchicine, and/or oral corticosteroids (if receiving these treatments) Exclusion Criteria: * Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases. * History of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency. * Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent pericarditis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic recurrent pericarditis pericarditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent pericarditis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Local Site #840001

    RECRUITING

    Houston, Texas, 77034, United States

  • Local Site #840002

    WITHDRAWN

    Park Ridge, Illinois, 60068, United States

  • Local Site #840004

    RECRUITING

    Richmond, Virginia, 23219, United States

  • Local Site #840005

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Local Site #840008

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Local Site #840010

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Local Site #840011

    WITHDRAWN

    Owensboro, Kentucky, 42303, United States

  • Local Site #840012

    WITHDRAWN

    Tucson, Arizona, 85718, United States

  • Local Site #840013

    RECRUITING

    Salt Lake City, Utah, 84132, United States

  • Local Site #840014

    RECRUITING

    Orange, California, 92868, United States

  • Local Site #840016

    RECRUITING

    Saint Augustine, Florida, 32086, United States

  • Local Site #840017

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Local Site #840018

    RECRUITING

    Charlottesville, Virginia, 22908, United States

  • Local Site #840019

    RECRUITING

    Houston, Texas, 77030, United States

  • Local Site #840020

    RECRUITING

    New York, New York, 10032, United States

  • Local Site #840021

    RECRUITING

    Seattle, Washington, 98105, United States

  • Local Site #840022

    RECRUITING

    Burlington, Vermont, 05401, United States

  • Local Site #840101

    RECRUITING

    Ottawa, Ontario, K1Y 4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.